AAAAAA

   
Results: 1-16 |
Results: 16
Three independent yearly analyses of the spectrum and potency of metronidazole: A multicenter study of 1,108 contemporary anaerobic clinical isolates
Authors: Erwin, ME Fix, AM Jones, RN
Citation: Me. Erwin et al., Three independent yearly analyses of the spectrum and potency of metronidazole: A multicenter study of 1,108 contemporary anaerobic clinical isolates, DIAG MICR I, 39(2), 2001, pp. 129-132
Evaluation of gemifloxacin (SB-265805, LB20304a): in vitro activity against over 6000 Gram-positive pathogens from diverse geographic areas
Authors: Jones, RN Pfaller, MA Erwin, ME
Citation: Rn. Jones et al., Evaluation of gemifloxacin (SB-265805, LB20304a): in vitro activity against over 6000 Gram-positive pathogens from diverse geographic areas, INT J ANT A, 15(3), 2000, pp. 227-230
Development of gemifloxacin in vitro susceptibility test methods for gonococci including quality control guidelines
Authors: Jones, RN Erwin, ME
Citation: Rn. Jones et Me. Erwin, Development of gemifloxacin in vitro susceptibility test methods for gonococci including quality control guidelines, DIAG MICR I, 37(3), 2000, pp. 195-201
Anti-gonococcal activity of gemifloxacin against fluoroquinolone-resistantstrains and a comparison of agar dilution and Etest methods
Authors: Jones, RN Deshpande, LM Erwin, ME Barrett, MS Beach, ML
Citation: Rn. Jones et al., Anti-gonococcal activity of gemifloxacin against fluoroquinolone-resistantstrains and a comparison of agar dilution and Etest methods, J ANTIMICRO, 45, 2000, pp. 67-70
Determination of MIC quality control ranges for ABT-733, a novel ketolide antimicrobial agent
Authors: Marshall, SA Erwin, ME Jones, RN
Citation: Sa. Marshall et al., Determination of MIC quality control ranges for ABT-733, a novel ketolide antimicrobial agent, J CLIN MICR, 38(6), 2000, pp. 2462-2463
Quality control guidelines for disk diffusion and broth microdilution antimicrobial susceptibility tests with seven drugs for veterinary applications
Authors: Odland, BA Erwin, ME Jones, RN
Citation: Ba. Odland et al., Quality control guidelines for disk diffusion and broth microdilution antimicrobial susceptibility tests with seven drugs for veterinary applications, J CLIN MICR, 38(1), 2000, pp. 453-455
Development of in vitro susceptibility testing methods for gemifloxacin (formerly LB20304a or SB-265805), an investigational fluoronaphthyridone
Authors: Jones, RN Erwin, ME Biedenbach, DJ Johnson, DM Pfaller, MA
Citation: Rn. Jones et al., Development of in vitro susceptibility testing methods for gemifloxacin (formerly LB20304a or SB-265805), an investigational fluoronaphthyridone, DIAG MICR I, 35(3), 1999, pp. 227-234
Comparative antimicrobial activity of gatifloxacin tested against Streptococcus spp. including quality control guidelines and etest method validation
Authors: Jones, RN Johnson, DM Erwin, ME Beach, ML Biedenbach, DJ Pfaller, MA
Citation: Rn. Jones et al., Comparative antimicrobial activity of gatifloxacin tested against Streptococcus spp. including quality control guidelines and etest method validation, DIAG MICR I, 34(2), 1999, pp. 91-98
Comparative antimicrobial activity of gatifloxacin tested against Campylobacter jejuni including fluoroquinolone-resistant clinical isolates
Authors: Hayward, CL Erwin, ME Barrett, MS Jones, RN
Citation: Cl. Hayward et al., Comparative antimicrobial activity of gatifloxacin tested against Campylobacter jejuni including fluoroquinolone-resistant clinical isolates, DIAG MICR I, 34(2), 1999, pp. 99-102
Antimicrobial activity and spectrum of SCH27899 (Ziracin (R)) tested against Gram-positive species including recommendations for routine susceptibility testing methods and quality control
Authors: Jones, RN Marshall, SA Erwin, ME
Citation: Rn. Jones et al., Antimicrobial activity and spectrum of SCH27899 (Ziracin (R)) tested against Gram-positive species including recommendations for routine susceptibility testing methods and quality control, DIAG MICR I, 34(2), 1999, pp. 103-110
Gatifloxacin (AM-1155, CG 5501) susceptibility testing interpretive criteria and quality control guidelines for dilution and disk (5-mu g) diffusion methods
Authors: Jones, RN Kugler, KC Erwin, ME Biedenbach, DJ Beach, ML Pfaller, MA
Citation: Rn. Jones et al., Gatifloxacin (AM-1155, CG 5501) susceptibility testing interpretive criteria and quality control guidelines for dilution and disk (5-mu g) diffusion methods, DIAG MICR I, 33(4), 1999, pp. 247-253
Anti-streptococcal activity of SB-265805 (LB20304), a novel fluoronaphthyridone, compared with five other compounds, including quality control guidelines
Authors: Johnson, DM Jones, RN Erwin, ME
Citation: Dm. Johnson et al., Anti-streptococcal activity of SB-265805 (LB20304), a novel fluoronaphthyridone, compared with five other compounds, including quality control guidelines, DIAG MICR I, 33(2), 1999, pp. 87-91
Antimicrobial activity of SCH27899 (Ziracin (R)), a novel everninomicin derivative, tested against Streptococcus spp.: Disk diffusion/etest method evaluations and quality control guidelines
Authors: Marshall, SA Jones, RN Erwin, ME
Citation: Sa. Marshall et al., Antimicrobial activity of SCH27899 (Ziracin (R)), a novel everninomicin derivative, tested against Streptococcus spp.: Disk diffusion/etest method evaluations and quality control guidelines, DIAG MICR I, 33(1), 1999, pp. 19-25
Activity of gatifloxacin against Haemophilus influenzae and Moraxella catarrhalis, including susceptibility test development, E-test comparisons, andquality control guidelines for H-influenzae
Authors: Jones, RN Biedenbach, DJ Erwin, ME Beach, ML Pfaller, MA
Citation: Rn. Jones et al., Activity of gatifloxacin against Haemophilus influenzae and Moraxella catarrhalis, including susceptibility test development, E-test comparisons, andquality control guidelines for H-influenzae, J CLIN MICR, 37(6), 1999, pp. 1999-2002
Studies to establish quality control ranges for SB-265805 (LB20304) when using national committee for clinical laboratory standards antimicrobial susceptibility test methods
Authors: Erwin, ME Jones, RN
Citation: Me. Erwin et Rn. Jones, Studies to establish quality control ranges for SB-265805 (LB20304) when using national committee for clinical laboratory standards antimicrobial susceptibility test methods, J CLIN MICR, 37(1), 1999, pp. 279-280
The prevalence of fluoroquinolone resistance among clinically significant respiratory tract isolates of Streptococcus pneumoniae in the United Statesand Canada - 1997 results from the SENTRY Antimicrobial Surveillance Program
Authors: Doern, GV Pfaller, MA Erwin, ME Brueggemann, AB Jones, RN
Citation: Gv. Doern et al., The prevalence of fluoroquinolone resistance among clinically significant respiratory tract isolates of Streptococcus pneumoniae in the United Statesand Canada - 1997 results from the SENTRY Antimicrobial Surveillance Program, DIAG MICR I, 32(4), 1998, pp. 313-316
Risultati: 1-16 |